FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE and CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Overview

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #19 most commonly reported adverse reaction for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, manufactured by GlaxoSmithKline LLC. There are 1,961 FDA adverse event reports linking FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 1.2% of all 162,228 adverse event reports for this drug.

Patients taking FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is a less commonly reported adverse event for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, but still significant enough to appear in the safety profile.

Other Side Effects of FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE:

• DYSPNOEA — 9,751 reports
• ASTHMA — 7,923 reports
• DRUG INEFFECTIVE — 5,357 reports
• COUGH — 4,772 reports
• PNEUMONIA — 4,764 reports
• WHEEZING — 4,065 reports
• FATIGUE — 3,868 reports
• MALAISE — 3,509 reports
• HEADACHE — 3,492 reports
• PAIN — 3,234 reports

Other Drugs Associated with CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:

Does FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE cause CHRONIC OBSTRUCTIVE PULMONARY DISEASE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 1,961 FDA reports for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CHRONIC OBSTRUCTIVE PULMONARY DISEASE with FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 1.2% of all adverse event reports for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, making it a notable side effect.

What should I do if I experience CHRONIC OBSTRUCTIVE PULMONARY DISEASE while taking FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE?

If you experience chronic obstructive pulmonary disease while taking FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages